Therapeutic Pipeline

AmideBio has leveraged its core manufacturing technology to pursue a series of therapeutic targets that include, ultrastable and ultraconcentrated insulin for T2 diabetes , glucose responsive insulin for T1 and T2 diabetes, solution stable glucagon for hyperinsulinism and similar orphan indications as well as the the development of diagnostics for early detection of T1 diabetes.

PROGRAM

INDICATION

DISCOVERY

PRECLINICAL

IND ENABLING

AB-SCI-0177

T2 DIABETES

AB-GLC-0035

HYPERINSULINISM

AB-GRI-0084

T1/T2 DIABETES

AB-DIG-0014

T1 DIAGNOSTIC

COMPANY NEWS

AMIDEBIO Awarded $1.56M SBIR Phase II Grant to Further Development of its Novel Glucagons for the Treatment of Hyperinsulinism2019-09-30 - 07:33
AmideBio, LLC, a privately held biopharmaceutical company, announced today that it has received $1.56M in funding through a Phase II Small Business Innovation Research (SBIR) grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The goal of this two-year grant is to enable an Investigational New Drug (IND) filing with the […]
David Brunel Takes Over Chairmanship at AmideBio2018-11-16 - 08:47
AmideBio LLC, a privately held biopharmaceutical company, announced today that David Brunel, a board member of AmideBio, has assumed the role of Chairman of the Board, replacing Misha Plam. Dr. Plam, a founder of AmideBio who retired recently as President and CEO, is now Chairman Emeritus. Read the full press release.
Diabetes Industry Veteran Pawel Fludzinski, Ph.D. assumed role of Company President of AmideBio2018-09-03 - 22:37
AmideBio LLC, a privately held biopharmaceutical company, announced today that Pawel Fludzinski, Ph.D. has assumed the role of Company President in addition to Chief Executive Officer, effective immediately. Dr. Misha Plam is retiring from the role but will remain Chairman of the Board of Directors. Read the full press release.